1. Home
  2. ENTA

ENTA

Enanta Pharmaceuticals Inc.

Logo Enanta Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 3:33pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Founded: 1995 Country:
United States
United States
Employees: N/A City: WATERTOWN
Market Cap: 369.4M IPO Year: 2013
Target Price: $19.33 AVG Volume (30 days): 244.9K
Analyst Decision: Hold Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -6.56 EPS Growth: N/A
52 Week Low/High: $8.08 - $38.79 Next Earning Date: 05-06-2024
Revenue: $73,622,000 Revenue Growth: -10.32%
Revenue Growth (this year): -12.66% Revenue Growth (next year): 10.48%

Share on Social Networks: